Literature DB >> 17596429

Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines.

Mohan Babu Appaiahgari1, Ravindra Mohan Pandey, Sudhanshu Vrati.   

Abstract

We determined the levels of adenovirus 5 (Ad5) neutralizing antibodies in children in India less than 2 years of age. The results clearly show an age-dependent increase in Ad5-specific immunity, with 7- to 12-month-old children having the lowest levels of Ad5 immunity. This opens up the scope for the use of recombinant Ad5-based vaccines in this age group.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17596429      PMCID： PMC2044479          DOI： 10.1128/CVI.00173-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  21 in total

1.  Prevalence of adenovirus types 3 and 7 antibodies in Singapore.

Authors:  O Nishio; K Matsui; K T Goh; Y Matsunaga; S Inouye
Journal:  Jpn J Infect Dis       Date:  2001-06       Impact factor: 1.362

2.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector.

Authors:  Stefan Kostense; Wouter Koudstaal; Mieke Sprangers; Gerrit Jan Weverling; Germaine Penders; Niels Helmus; Ronald Vogels; Margreet Bakker; Ben Berkhout; Menzo Havenga; Jaap Goudsmit
Journal:  AIDS       Date:  2004-05-21       Impact factor: 4.177

4.  Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States.

Authors:  Edward Nwanegbo; Eftyhia Vardas; Wentao Gao; Hilton Whittle; Huijie Sun; David Rowe; Paul D Robbins; Andrea Gambotto
Journal:  Clin Diagn Lab Immunol       Date:  2004-03

5.  A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.

Authors:  Nina Malkevitch; L Jean Patterson; Kristine Aldrich; Ersell Richardson; W Gregory Alvord; Marjorie Robert-Guroff
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

6.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

7.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Gene transduction and cell entry pathway of fiber-modified adenovirus type 5 vectors carrying novel endocytic peptide ligands selected on human tracheal glandular cells.

Authors:  Florence Gaden; Laure Franqueville; Maria K Magnusson; Saw See Hong; Marc D Merten; Leif Lindholm; Pierre Boulanger
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Neutralizing antibodies against 33 human adenoviruses in normal children in Rome.

Authors:  E D'Ambrosio; N Del Grosso; A Chicca; M Midulla
Journal:  J Hyg (Lond)       Date:  1982-08

10.  An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism.

Authors:  Joel N Glasgow; Eric J Kremer; Akseli Hemminki; Gene P Siegal; Joanne T Douglas; David T Curiel
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616
View more
  18 in total

1.  Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector.

Authors:  William D Pratt; Danher Wang; Donald K Nichols; Min Luo; Jan Woraratanadharm; John M Dye; David H Holman; John Y Dong
Journal:  Clin Vaccine Immunol       Date:  2010-02-24

2.  Development of a method for effective amplification of human adenovirus 40.

Authors:  Satoshi Yamasaki; Yoshiaki Miura; Eric Brown; Julia Davydova; Masato Yamamoto
Journal:  Arch Virol       Date:  2010-05-21       Impact factor: 2.574

3.  Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.

Authors:  Qianqian Li; Qiang Liu; Weijing Huang; Aijing Song; Chenyan Zhao; Jiajing Wu; Youchun Wang
Journal:  Hum Vaccin Immunother       Date:  2017-03-16       Impact factor: 3.452

4.  Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Authors:  Maria Bunuales; Eva Garcia-Aragoncillo; Raquel Casado; José Ignacio Quetglas; Sandra Hervas-Stubbs; Sergia Bortolanza; Carolina Benavides-Vallve; Carlos Ortiz-de-Solorzano; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

5.  Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity.

Authors:  Matthew J Johnson; Constantinos Petrovas; Takuya Yamamoto; Ross W B Lindsay; Karin Loré; Jason G D Gall; Emma Gostick; François Lefebvre; Mark J Cameron; David A Price; Elias Haddad; Rafick-Pierre Sekaly; Robert A Seder; Richard A Koup
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

6.  Adenoviruses in lymphocytes of the human gastro-intestinal tract.

Authors:  Soumitra Roy; Roberto Calcedo; Angelica Medina-Jaszek; Martin Keough; Hui Peng; James M Wilson
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

Review 7.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

8.  Comparison of two high-throughput assays for quantification of adenovirus type 5 neutralizing antibodies in a population of donors in China.

Authors:  Qiang Liu; Jianhui Nie; Weijin Huang; Shufang Meng; Baozhu Yuan; Dongying Gao; Xuemei Xu; Youchun Wang
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

9.  Novel vaccines to human rabies.

Authors:  Hildegund C J Ertl
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

10.  A serological survey of human adenovirus serotype 2 and 5 circulating pediatric populations in Changchun, China, 2011.

Authors:  Bin Yu; Zhen Wang; Jianing Dong; Chu Wang; Lina Gu; Caijun Sun; Wei Kong; Xianghui Yu
Journal:  Virol J       Date:  2012-11-23       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.